Floatz logo

ADENOSINE, N-CYCLOPENTYL-

Refractory Diffuse Large B-cell Lymphoma

ImmunoVaccine Technologies, Inc. (IMV Inc.)Small moleculePhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
81/ 100

Competitive context

5 Active assets in the Refractory Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Pyrotinib
BeiGene
Phase 1/2CCC
Tislelizumab
BeiGene
Phase 1/2CCC
rc48-adc
BeiGene
Phase 1/2CCC
Ruxolitinib
National Health Research Institutes, Taiwan
Phase 1/2CC
Efineptakin Alfa
NeoImmuneTech
Phase 1CC

Same molecule, other indications

ADENOSINE, N-CYCLOPENTYL- is also rated in:

metastatic neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
breast cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →